Nektar Therapeutics
NKTR
$56.23
-$0.39-0.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -36.24% | -43.89% | -32.79% | -19.56% | -3.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.24% | -43.89% | -32.79% | -19.56% | -3.24% |
| Cost of Revenue | -- | -- | -73.40% | -67.33% | -37.14% |
| Gross Profit | -14.54% | -18.47% | -13.50% | 13.33% | 18.52% |
| SG&A Expenses | -28.64% | -10.52% | -3.01% | -2.04% | 5.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.60% | -18.54% | -13.13% | -6.22% | 1.91% |
| Operating Income | 10.85% | -0.66% | -0.34% | -2.98% | -5.41% |
| Income Before Tax | -18.79% | -37.76% | 28.01% | 30.76% | 24.33% |
| Income Tax Expenses | 17.11% | 42.26% | -4,655.56% | -388.61% | 11.63% |
| Earnings from Continuing Operations | -18.83% | -37.92% | 28.26% | 30.95% | 24.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.83% | -37.92% | 28.26% | 30.95% | 24.34% |
| EBIT | 10.85% | -0.66% | -0.34% | -2.98% | -5.41% |
| EBITDA | 9.30% | -3.36% | -3.85% | -6.59% | -8.83% |
| EPS Basic | 11.52% | -17.06% | 36.88% | 35.55% | 31.00% |
| Normalized Basic EPS | 30.06% | 7.13% | 1.87% | -4.66% | -4.09% |
| EPS Diluted | 11.61% | -16.94% | 36.80% | 35.48% | 30.94% |
| Normalized Diluted EPS | 29.80% | 6.77% | 2.25% | -4.28% | -3.71% |
| Average Basic Shares Outstanding | 39.61% | 22.90% | 13.98% | 7.16% | 9.52% |
| Average Diluted Shares Outstanding | 38.97% | 22.33% | 14.46% | 7.65% | 10.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |